CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of renal cell carcinoma (RCC).
  
  OVERVIEW OF ACTIVITY
  A recent explosion of clinical research developments has added renewed excitement and optimism to the field of RCC treatment. Specifically, over the past few years a number of scientific breakthroughs related to the care of patients with relapsed/refractory RCC have translated into new therapeutic options, the rapid emergence of which has added complexity to traditional decision-making. Similarly, the unique toxicities and practical nuances associated with the use of these agents have created additional and important considerations that clinicians must weigh and account for in order to make the best possible treatment recommendations. In addition, as is common across cancer medicine, much interest has been expressed in moving the increasing number of treatments for metastatic RCC into earlier lines of therapy in the hopes of improving outcomes for patients with localized disease.
  
  These video proceedings from a CME symposium held during the 2018 ASCO Annual Meeting feature discussions with leading researchers with an expertise in genitourinary cancers regarding actual cases of RCC from their practices and the published data that drive clinical decision-making for patients in those and diverse other situations. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, hematology-oncology fellows and other allied healthcare professionals with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES

  • Appraise recent data on diagnostic and therapeutic advances in RCC, and integrate this information, as appropriate, into current clinical care.
  • Develop an evidence-based approach to the sequencing of systemic therapies for patients with advanced RCC, incorporating tyrosine kinase inhibitors, anti-VEGF antibodies, mTOR inhibitors and immunotherapeutic agents.
  • Appreciate the recent FDA approval of nivolumab in combination with ipilimumab as front-line treatment for intermediate- and poor-risk advanced RCC, and develop strategies to optimally integrate these agents into the clinical care of patients.
  • Recognize toxicities attributable to diverse systemic treatments for RCC, and offer preventive or emergent interventions to minimize or ameliorate these side effects.
  • Appraise emerging clinical trial data evaluating anti-PD-1/PD-L1 antibodies in combination with other immunotherapeutic or targeted agents for previously untreated or relapsed metastatic RCC, and prepare for the potential availability of these approaches in routine practice.
  • Recall available and emerging data with other investigational agents and strategies currently in testing for RCC and, where applicable, refer eligible patients for trial participation or other expanded access programs.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  David F McDermott, MD
  Professor of Medicine
  Harvard Medical School
  Director, Biologic Therapy and Cutaneous Oncology Programs
  Beth Israel Deaconess Medical Center
  Leader, Kidney Cancer Program
  Dana-Farber Cancer Center
  Boston, Massachusetts
  
  Consulting Agreements: Array BioPharma Inc, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Genentech, Merck, Novartis, Pfizer Inc; Contracted Research: Bristol-Myers Squibb Company, Prometheus Laboratories Inc.
  
  Thomas Powles, MBBS, MRCP, MD
  Professor of Urology Oncology
  Director of St Bartholomew’s Cancer Centre
  Queen Mary University of London
  London, United Kingdom
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc.
  
  David I Quinn, MBBS, PhD
  Medical Director, Norris Cancer Hospital and Clinics
  Head, GU Cancer Section
  Division of Cancer Medicine and Blood Diseases
  USC/Norris Comprehensive Cancer Center
  Los Angeles, California
  
  Advisory Committee: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, Exelixis Inc, Genentech, Janssen Biotech Inc, Merck, Pfizer Inc, Sanofi Genzyme; Consulting Agreements: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Dendreon Pharmaceuticals Inc, Exelixis Inc, Genentech, Janssen Biotech Inc, Merck, Pfizer Inc, Sanofi Genzyme.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Bristol-Myers Squibb Company, Eisai Inc and Genentech.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: August 2018
  Expiration date: August 2019